How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-52
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014;89(2):225-40
   PubMed Web of Science ®Google Scholar
• Happe LE. Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice. Am J Manag Care 2013;19(17 Suppl):s332-42
   Google Scholar
• Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: canadian MS Working Group updated recommendations. Can J Neurol Sci 2013;40(3):307-23
   PubMed Web of Science ®Google Scholar
• Norbis L, Miotto P, Alagna R, Cirillo DM. Tuberculosis: lights and shadows in the current diagnostic landscape. New Microbiol 2013;36(2):111-20
   PubMedGoogle Scholar
• Fritsche A, Engel R, Buhl D, Zellweger JP. Mycobacterium bovis tuberculosis: from animal to man and back. Int J Tuberc Lung Dis 2004;8(7):903-4
   PubMedGoogle Scholar
• de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum - review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis 2010;4:e744
   Google Scholar
• Panteix G, Gutierrez MC, Boschiroli ML, et al. Pulmonary tuberculosis due to Mycobacterium microti: a study of six recent cases in France. J Med Microbiol 2010;59(Pt 8):984-9
   PubMedGoogle Scholar
• Buonora N, Chiavarini M, Salmasi L, et al. Impact of immigration on burden of tuberculosis in Umbria: a low-incidence Italian region with high immigrants rates. J Prev Med Hyg 2013;54(1):29-34
   PubMedGoogle Scholar
• Lawn SD, Zumla AI. Tuberculosis. Lancet 2011;378(9785):57-72
   PubMed Web of Science ®Google Scholar
• Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163(9):1009-21
   PubMed Web of Science ®Google Scholar
• Frieden TR. Six components necessary for effective public health program implementation. Am J Public Health 2014;104(1):17-22
   PubMed Web of Science ®Google Scholar
• Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis. Lancet 2003;362(9387):887-9
   PubMed Web of Science ®Google Scholar
• Dye C. Making wider use of the world’s most widely used vaccine: bacille Calmette-Guerin revaccination reconsidered. J R Soc Interface 2013;10(87):20130365
   PubMed Web of Science ®Google Scholar
• Barreto ML, Cunha SS, Pereira SM, et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis 2005;9(10):1171-3
   PubMedGoogle Scholar
• Chiang CY, Riley LW. Exougenous reinfection in tuberculosis. Lancet Infect Dis 2005;5(10):629-36
   PubMed Web of Science ®Google Scholar
• Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 2012;12(5):352-66
   PubMed Web of Science ®Google Scholar
• Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med 2011;183(6):696-707
   PubMed Web of Science ®Google Scholar
• Rajni Rao N, Meena LS. Biosynthesis and virulent behavior of lipids produced by Mycobacterium tuberculosis: LAM and cord factor: an overview. Biotechnol Res Int 2011;2011:274693
   PubMedGoogle Scholar
• Walzl G, Ronacher K, Hanekom W, et al. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011;11(5):343-54
   PubMed Web of Science ®Google Scholar
• Bozzano F, Marras F, De Maria A. Immunology of tuberculosis. Mediterr J Hematol Infect Dis 2014;6(1):e2014027
   Google Scholar
• Coelho Filho JC, Takenami I, Arruda S. Revisiting the Rich’s formula: an update about granulomas in human tuberculosis. Braz J Infect Dis 2013;17(2):234-8
   PubMedGoogle Scholar
• Prezzemolo T, Giggino G, La Manna MP, et al. Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. Front Immunol 2014;5:180
   PubMed Web of Science ®Google Scholar
• Brighenti S, Andersson J. Local immune responses in human tuberculosis: learning from the site of infection. J Infect Dis 2012;205(Suppl 2):S316-24
   Google Scholar
• Feng CG, Kaviratne M, Rothfuchs AG, et al. NK cell-derived IFN-gamma differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol 2006;177(10):7086-93
   PubMedGoogle Scholar
• Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1988;393(6685):537-44
   Google Scholar
• Hoffmann C, Leis A, Niederweis M, et al. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci USA 2008;105(10):3963-7
   PubMed Web of Science ®Google Scholar
• Delogu G, Sali M, Fadda G. The biology of mycobacterium tuberculosis infection. Mediterr J Hematol Infect Dis 2013;5:e2013070
   PubMedGoogle Scholar
• Boshoff HI, Lun DS. Systems biology approaches to understanding mycobacterial survival mechanisms. Drug Discov Today Dis Mech 2010;7(1):e75-82
   Google Scholar
• Abdallah AM, Gey van Pittius NC, Champion PA, et al. Type VII secretion--mycobacteria show the way. Nat Rev Microbiol 2007;5(11):883-91
   PubMedGoogle Scholar
• Houben EN, Bestebroer J, Ummels R, et al. Composition of the type VII secretion system membrane complex. Mol Microbiol 2012;86(2):472-84
   PubMed Web of Science ®Google Scholar
• Volkman HE, Pozos TC, Zheng J, et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010;327(5964):466-9
   PubMed Web of Science ®Google Scholar
• Korch SB, Contreras H, Clark-Curtiss JE. Three Mycobacterium tuberculosis Rel toxin-antitoxin modules inhibit mycobacterial growth and are expressed in infected human macrophages. J Bacteriol 2009;191(5):1618-30
   PubMedGoogle Scholar
• Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(Suppl 2):S231-79
   PubMedGoogle Scholar
• Hernandez C, Cetner AS, Jordan JE, et al. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008;59(3):363-80
   PubMedGoogle Scholar
• Esmail H, Barry CE 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014;369(1645):20130437
   PubMed Web of Science ®Google Scholar
• Rich AR. The pathogenesis of tuberculosis. 2 edition. Charles Thomas; IL, USA: 1951
   Google Scholar
• Hosoğlu S, Ayaz C, Geyik MF, et al. Tuberculous meningitis in adults: an eleven-year review. Int J Tuberc Lung Dis 1998;2(7):553-7
   PubMedGoogle Scholar
• Be NA, Kim KS, Bishai WR, Jain SK. Pathogenesis of central nervous system tuberculosis. Curr Mol Med 2009;9(2):94-9
   PubMedGoogle Scholar
• Ghosh K, Patwardhan M, Pradhan V. Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas. Rheumatol Int 2009;29(9):1047-50
   PubMedGoogle Scholar
• Pradhan V, Patwardhan M, Athavale A, et al. Mycobacterium tuberculosis triggers autoimmunity? Indian J Tuberc 2012;59(1):49-51
   PubMedGoogle Scholar
• Lee J, Reinke EK, Zozulya AL, et al. Mycobacterium bovis bacille Calmette-Guérin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner. J Immunol 2008;181(9):6201-12
   PubMed Web of Science ®Google Scholar
• Bible E. Multiple sclerosis: disease activity is reduced in CIS after BCG vaccination. Nat Rev Neurol 2014;10(2):62
   PubMedGoogle Scholar
• Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001;108(8):1097-104
   PubMed Web of Science ®Google Scholar
• Chodisetti SB, Rai PK, Gowthaman U, et al. Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis. BMC Immunology 2012;13:13
   PubMedGoogle Scholar
• Moseley P. Stress proteins and the immune response. Immunopharmacology 2000;48(3):299-302
   PubMedGoogle Scholar
• Mycko MP, Brosnan CF, Raine CS, et al. Transcriptional profiling of microdissected areas of active multiple sclerosis lesions reveals activation of heat shock protein genes. J Neurosci Res 2012;90(10):1941-8
   PubMedGoogle Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;6:183-200
   Google Scholar
• Shaik J, Pillay M, Jeena P. The role of interferon gamma release assays in the monitoring of response to anti-tuberculosis treatment in children. Paediatr Respir Rev 2013;13:S1526-0542
   Google Scholar
• Beamer GL, Cyktor J, Carruthers B, Turner J. H-2 alleles contribute to antigen 85-specific interferon-gamma responses during Mycobacterium tuberculosis infection. Cell Immunol 2011;271(1):53-61
   PubMedGoogle Scholar
• Todd PA, Goa KL. Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 1992;43(1):111-22
   PubMedGoogle Scholar
• Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Clin Ther 2010;32(11):1871-88
   PubMed Web of Science ®Google Scholar
• Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013;12(5):543-53
   PubMed Web of Science ®Google Scholar
• Dheda K, Schwander SK, Zhu B, et al. The immunology of tuberculosis: from bench to bedside. Respirology 2010;15(3):433-50
   PubMed Web of Science ®Google Scholar
• Musabak U, Demirkaya S, Genç G, et al. Serum adiponectin, TNF-α, IL-12p70 and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. Neuroimmunomodulation 2011;18(1):57-66
   PubMedGoogle Scholar
• Winkelmann A, Loebermann M, Reisinger EC, Zettl UK. Multiple sclerosis treatment and infections issues: update 2013. Clin Exp Immunol 2014;175(3):425-38
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401
   PubMed Web of Science ®Google Scholar
• Connor LM, Harvie MC, Rich FJ, et al. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol 2010;40(9):2482-92
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10(8):745-58
   PubMed Web of Science ®Google Scholar
• Abonia JP, Hallgren J, Jones T, et al. Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 2006;108(5):1588-94
   PubMedGoogle Scholar
• Mulero P, Caminero AB, Neri Crespo MJ, et al. Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab. J Neuroimmunol 2012;243(1-2):103-5
   PubMedGoogle Scholar
• Dahdaleh D, Altmann DM, Malik O, Nicholas RS. Breathlessness, night sweats, and weight loss on natalizumab. Lancet 2012;380(9843):726-7
   PubMed Web of Science ®Google Scholar
• Anderson C, Hopkins S, Adeboyeku D, Maguire H. Tuberculosis in London: not unexpected. Lancet 2013;381(9862):201
   PubMedGoogle Scholar
• Boumpas DT, Paliogianni F, Anastassiou ED, Balow JE. Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol 1991;9(4):413-23
   PubMed Web of Science ®Google Scholar
• Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001;117(1-2):1-8
   PubMedGoogle Scholar
• Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13(3):223-37
   PubMed Web of Science ®Google Scholar
• Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997;23(2):219-37
   PubMed Web of Science ®Google Scholar
• Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26
   PubMed Web of Science ®Google Scholar
• Cline JC, Davis SM. Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Ann Pharmacother 1997;31(6):775-6
   PubMedGoogle Scholar
• Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 2002;31(5):296-300
   PubMed Web of Science ®Google Scholar
• Hirata N, Koerner MM, Tenderich G, et al. Influence of cytoimmunological state on the development of tuberculosis in heart transplant recipients. Surg Today 2001;31(6):482-6
   PubMedGoogle Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111(8):1133-45
   PubMed Web of Science ®Google Scholar
• Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80(2):131-2
   PubMed Web of Science ®Google Scholar
• Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007(4):CD003982
   Google Scholar
• Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des 1999;5(8):627-43
   PubMedGoogle Scholar
• Agency BC. Cancer drug manual: cyclophosphamide. 2013. p. 1-12
   Google Scholar
• Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001;40(3):341-2
   PubMed Web of Science ®Google Scholar
• Zorlu M, Kiskac M, Karatoprak C, et al. Pott’s disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy. Indian J Pharmacol 2013;45(6):631-3
   PubMed Web of Science ®Google Scholar
• Mor A, Bingham CO III, Kishimoto M, et al. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic. Ann Rheumatol Dis 2008;67(4):462-5
   PubMedGoogle Scholar
• Wehenkel A, Fernandez P, Bellinzoni M, et al. The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria. FEBS Lett 2006;580(13):3018-22
   PubMedGoogle Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013;5:CD002127
   PubMedGoogle Scholar
• Darlington PJ, Boivin MN, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother 2011;11(9):1295-303
   PubMed Web of Science ®Google Scholar
• Russo RL, Dulley FL, Suganuma L, et al. Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int J Infect Dis 2010;14:e187-91
   Google Scholar
• Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect 2006;62(4):421-6
   PubMed Web of Science ®Google Scholar
• de la Câmara R, Martino R, Granados E, et al. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. Bone Marrow Transplant 2000;26(3):291-8
   PubMed Web of Science ®Google Scholar
• Holloman J, Ho CC, Hukki A, et al. The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. Am J Stem Cell 2013;2(2):95-107
   PubMedGoogle Scholar
• Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin 2014;30(2):251-62
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
   PubMed Web of Science ®Google Scholar
• Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol 2013;33(1):56-65
   PubMed Web of Science ®Google Scholar
• Montoya MC, Sancho D, Bonello G, et al. Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. Nat Immunol 2002;3(2):159-68
   PubMed Web of Science ®Google Scholar
• Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005;52(9):2730-9
   PubMed Web of Science ®Google Scholar
• Minagar A, Alexander JS, Sahraian MA, Zivadinov R. Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opin Biol Ther 2010;10:421-9
   PubMed Web of Science ®Google Scholar
• Willis M, Robertson NP. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2014;13(8):1115-24
   PubMed Web of Science ®Google Scholar
• Antohe I, Dascalescu A, Burcoveanu C, et al. Pact with the devil: alemtuzumab therapy, immune suppression and infectious complications in chronic lymphocytic leukemia. Rev Med Chir Soc Med Nat Iasi 2014;118:92-5
   PubMedGoogle Scholar
• Abad S, Gyan E, Moachon L, et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin Infect Dis 2003;37:e27-8
   Google Scholar
• Au WY, Leung AY, Tse EW, et al. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res 2008;32:547-51
   PubMed Web of Science ®Google Scholar
• Bosch W, Poowanawittayakom N, Chaikriangkrai K, et al. Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy. Transpl Infect Dis 2013;15:E33-9
   Google Scholar
• Iannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol Suppl 2014;91:41-6
   PubMedGoogle Scholar
• Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G. Latent tuberculosis infection in patients with chronic plaque psoriasis candidate to biological therapy. Br J Dermatol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011;25:491-502
   PubMed Web of Science ®Google Scholar
• Racke MK, Lovett-Racke AE, Karandikar NJ. The mecanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010;74(Suppl 1):S25-30
   Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Kappos L. Natalizumab: targeting α4-integrins in multiple sclerosis. Neurodegener Dis 2008;5:16-22
   PubMed Web of Science ®Google Scholar
• Schaal AD. Alemtuzumab (Campath 1-H). Clin J Oncol Nurs 2005;9:630-2
   PubMedGoogle Scholar